Details for New Drug Application (NDA): 218640
✉ Email this page to a colleague
The generic ingredient in LUBIPROSTONE is lubiprostone. There are ten drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the lubiprostone profile page.
Summary for 218640
| Tradename: | LUBIPROSTONE |
| Applicant: | Ascent Pharms Inc |
| Ingredient: | lubiprostone |
| Patents: | 0 |
Pharmacology for NDA: 218640
| Mechanism of Action | Chloride Channel Activators |
Medical Subject Heading (MeSH) Categories for 218640
Suppliers and Packaging for NDA: 218640
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| LUBIPROSTONE | lubiprostone | CAPSULE;ORAL | 218640 | ANDA | Camber Pharmaceuticals, Inc. | 31722-403 | 31722-403-60 | 60 CAPSULE in 1 BOTTLE (31722-403-60) |
| LUBIPROSTONE | lubiprostone | CAPSULE;ORAL | 218640 | ANDA | Camber Pharmaceuticals, Inc. | 31722-404 | 31722-404-60 | 60 CAPSULE in 1 BOTTLE (31722-404-60) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 8MCG | ||||
| Approval Date: | Jan 2, 2025 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 24MCG | ||||
| Approval Date: | Jan 2, 2025 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
